Close
CDMO Safety Testing 2026
Novotech

News

Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate

Avalon GloboCare Corp., a clinical-stage global developer of cell-based technologies and therapeutics, announced a strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine that can be administered by...

Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm

Roche announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible...

Gilead sets Covid-19 drug candidate remdesivir price at $390 per vial

Gilead Sciences has set the price of its investigational Covid-19 drug remdesivir at $390 per vial for the US and governments of other developed countries. Current treatment patterns reveal that most patients may require a five-day treatment course, which involves...

Astrazeneca: Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1

AstraZeneca announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease. Selumetinib is co-developed and co-commercialised with MSD Inc., Kenilworth, N.J., US (MSD: known...

Stevanato Group: planned investments under the 2020-2023 industrial plan – about 400 million euros to finance the company development

Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, continued its growth in 2019, recording a positive trend on key financial indicators. Indeed, the Group's consolidated revenues reached โ‚ฌ 570.3 million, an...

Takeda forms $900m research alliance with Carmine Therapeutics

Japanese pharmaceutical giant Takeda Pharmaceutical has entered into a research collaboration agreement with US-based Carmine Therapeutics for the discovery, development and commercialisation of rare disease therapies. The partners intend to leverage Carmineโ€™s REGENT technology, based on red blood cell extracellular...

CSL Behring to Acquire uniQure’s Late-Stage Hemophilia B Gene Therapy

Global biotherapeutics leader CSL Behring announced that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B from uniQure, a leading gene...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป